Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Account Payables (2022 - 2026)

Centessa Pharmaceuticals has reported Change in Account Payables over the past 4 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly Change in Account Payables fell 1017.48% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2025, up 101.09% year-over-year, with the annual reading at $50000.0 for FY2025, 101.09% up from the prior year.
  • Change in Account Payables was -$1.3 million for Q4 2025 at Centessa Pharmaceuticals, down from $3.3 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $3.3 million in Q3 2025 and troughed at -$4.2 million in Q1 2024.
  • The 4-year median for Change in Account Payables is $113000.0 (2023), against an average of -$56625.0.
  • Year-over-year, Change in Account Payables soared 1955.42% in 2024 and then tumbled 1017.48% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at $2.6 million in 2022, then tumbled by 77.43% to $586000.0 in 2023, then plummeted by 75.6% to $143000.0 in 2024, then tumbled by 1017.48% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Account Payables are -$1.3 million (Q4 2025), $3.3 million (Q3 2025), and $177000.0 (Q2 2025).